| Objective:To discuss the efficacy and the significance of neoadjuvant chemotherapy in advanced epithelial ovarian
cancer using different methods of administration.Methods:132 cases of initially treated epithelial ovarian cancer patients staged at IIIc to
IV were selected and randomly divided into four groups: Group A received paclitaxel intravenous chemotherapy alone, while Group B
were given carboplatin intra-peritoneal perfusion only, Group C received paclitaxel vein combined with carboplation intra-peritoneal, and
Group D had operations. Groups A, B and C received one course of neoadjuvant chemotherapy, after which the efficacy was evaluated
and then ovary tumor rebulking operations were performed, while Group D had operation without chemotherapy. The treatment efficacies
were compared among the four groups.Results:The satisfactory tumor remove rates were, respectively, 78.8%, 72.7%, 87.9% and
63.6% in the four groups. There were significance differences in tumor remove rates, operation time, intra-operative blood loss, and
post-operation evacuation time among the neoadjuvant chemotherapy groups (Groups a, b and C), as well as that between the
chemotherapy groups and GroupD (P<0.05). Adverse reactions in neoadjuvant chemotherapy groups were tolerable, operations were all
performed successfully, while myelosuppression and neurotoxicity were higher in Group C (P<0.01).Conclusion:(1) The neoadjuvant
chemotherapy can decrease the risk of operation, effectively improve the satisfactory tumor remove rate, as well as patients' life quality.
(2) Intravenous combined intraperitoneal perfusion has better clinical efficacy than drug use in one single method, with slightly higher yet
tolerable side effects. venous combining intraperitoneal perfusion is good way to clinical curative effect than channel alone, side effects
slightly higher but can tolerate. |
